Surgery for limited-stage small cell lung cancer: ready for prime-time?

Small cell lung cancer (SCLC) represents approximately 13% of all newly diagnosed lung cancers in the United States (1). Around 40% of the patients present with limited-stage (LS) disease, and 60% with extensive-stage (ES) (1).